Skip to main content
OpenTrials
Completed

NCT Number: NCT03407872

Safety and Pharmacokinetic Study of Inhaled Esketamine in Healthy Volunteers

The planned study is to determine the pharmacokinetic properties of Esketamine and safety assessment with inhaled Esketamine after different number of inhalations and different dosing sequences within three parts of the study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteers

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

BioResearch Group Sp. z o.o.

Kajetany, Poland

About this study

This is to be one-centre, single ascending dose and double-blind placebo controlled multiple dose three part study of Esketamine DPI (dry powder inhaler) in healthy volunteers.

PART A is a single dose, open-label part with Esketamine DPI inhalations administered with dose escalation between cohorts.

PART B is a single dose, open-label part with Esketamine DPI inhalations administered in different dosing sequences with dose escalation between cohorts.

PART C is a multiple dose, double-blind, placebo-controlled part with Esketamine DPI inhalations administered in different cycles of treatment (with four dosing sequences within two weeks) with dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.

Pharmacokinetic properties and safety of Esketamine DPI will be determined following different number of inhalations in PART A, different dosing sequences in PART B and different cycles of treatment in PART C.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Caucasian female or male,
  • Age: 18-55 years old, inclusive,
  • Body-mass index (BMI): ≥18.5 kg/m^2 and <29.9 kg/m^2
  • Non-smoker and nonuser of tobacco products for at least 1 year before screening,
  • Physical examination without any clinically relevant abnormality,
  • Laboratory values not clinically significant,
  • Volunteer (or his/her partner) of childbearing potential willingness to use acceptable forms of contraception.

Exclusion criteria

  • Known allergy or hypersensitivity to ketamine or its derivates and/or to any study product excipients,
  • Any known significant current or past acute or chronic disease or condition,
  • Participation in other clinical trial within 90 days preceding the screening,
  • Blood drawn within 30 days prior to inclusion to the study (more or equal to 300mL),
  • Positive results from pregnancy test for female participants,
  • Lactation in women participants,
  • Hypotension or hypertension in medical history,
  • Narcotic, alcohol addiction or abuse,
  • Participant who adhere to a special diet (e.g. low calories, vegetarian).

Treatment and study plan

Esketamine DPI

Drug

Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.

Placebo DPI

Drug

Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.

In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations.

Primary outcomes

  1. Cmax - maximum Esketamine plasma concentration

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

    The maximum concentration of the Esketamine in plasma after drug administration, obtained directly from the measured concentrations.

  2. AUC (0-24) - area under the Esketamine plasma concentration-time curve from time 0 to 24 hours after study drug administration

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

    The AUC(0-24) is a measure of total plasma exposure to the drug from time point zero to 24 hours after study drug administration.

  3. Number of inhalations needed to achieve the assumed Esketamine antidepressive plasma concentration.

    Time frame: up to 24 hours after study drug administration in PART A

  4. Number of inhalations within dosing sequence needed to maintain the assumed Esketamine antidepressive plasma concentration.

    Time frame: up to 24 hours after study drug administration in PART B

Secondary outcomes

  1. AUC (0-inf) - area under the Esketamine plasma concentration-time curve from time 0 to infinity time

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

    The AUC(0-inf) is a measure of total plasma exposure to the drug from time point zero extrapolated to infinity.

  2. Tmax - time to reach maximum Esketamine plasma concentration

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

    The Tmax is time to reach the maximum plasma concentration (Cmax), obtained directly from the actual sampling times.

  3. Kel -elimination rate constant

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

    Kel will be estimated via linear regression of time versus log of concentration.

  4. T1/2 - plasma elimination half-life for Esketamine

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

    T1/2 will be calculated as 0.693/Kel.

  5. Cmax - maximum Esnorketamine plasma concentration

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

    The maximum concentration of the Esnorketamine in plasma after drug administration, obtained directly from the measured concentrations. Esnorketamine is Esketamine's main metabolite.

  6. AUC (0-24) - area under the Esnorketamine plasma concentration-time curve from time 0 to 24 hours after study drug administration.

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

    The AUC(0-24) is a measure of total Esnorketamine plasma exposure to the metabolite from time point zero to 24 hours after study drug administration. Esnorketamine is Esketamine's main metabolite.

  7. Tmax - time to reach maximum Esnorketamine plasma concentration.

    Time frame: up to 24 hours after each study drug administration in PART A, B and C of the study.

    The Tmax is time to reach the maximum Esnorketamine plasma concentration (Cmax), obtained directly from the actual sampling times. Esnorketamine is Esketamine's main metabolite.

  8. Number of participants with adverse events (AEs) and Serious Adverse Events (SAEs).

    Time frame: up to 7 days in PART A and PART B of the study and up to 25 days in PART C of the study.

    Participants during hospitalization will be closely observed to assure maximal safety and to collect occurrence of all adverse event. To follow-up on all study participants telephone calls with a request for information regarding their health condition will be made. All adverse events will be collected with special attention to occurrence of psychotomimetic and dissociative effects after study drug administration.

Sponsors and collaborators

Lead sponsor

Celon Pharma SA

Industry

Collaborators

  • National Center for Research and Development, Poland

Registry information

Official study title

One-centre Safety and Pharmacokinetics Phase I Study of Inhaled Esketamine in Healthy Volunteers With Two Single Ascending Dose and One Double-blind Multiple Ascending Dose Parts

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jan 23, 2018
Registry last updated
Jul 12, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.